Your AI-Trained Oncology Knowledge Connection!
ASH 2024: Updates in the Treatment of CLL : Episode 14
Opinion
Video
Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024
Panelists discuss how novel Bruton tyrosine kinase (BTK) degraders like NX-5948 and BGB-16673 are showing promising early clinical activity in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on ASH 2024 data, while bispecific antibodies such as epcoritamab from the EPCORE CLL-1 trial represent another emerging therapeutic approach, though longer follow-up is needed to fully understand their optimal role in the treatment landscape.
Video content above is prompted by the following:
- There’s been a lot of emerging data with the BTK degraders in R/R CLL. Dr Kahl, what are your perspectives/insights on novel agents like NX-5948?
- What are your thoughts on agents like BGB-16673?
- Another exciting class is bispecifics in R/R CLL. Can you share the updated results with epcoritamab from the EPCORE CLL-1 trial?
Related Videos
Related Content
